(Q37690565)

22 August 2017

1 reference

title

Microtubules and resistance to tubulin-binding agents (English)

1 reference

22 August 2017

1

Maria Kavallaris

1 reference

PubMed ID

20147901

22 August 2017

language of work or name

English

0 references

publication date

11 February 2010

1 reference

22 August 2017

Nature Reviews Cancer

1 reference

22 August 2017

10

1 reference

22 August 2017

194-204

1 reference

22 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2803

22 August 2017

0 references

1 reference

Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-alpha tubulin

21 January 2018

1 reference

Microtubules are stabilized in confluent epithelial cells but not in fibroblasts

21 January 2018

1 reference

Tubulin dynamics in cultured mammalian cells

31 March 2020

1 reference

Microtubule dynamics at the G2/M transition: abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown and implications for spindle morphogenesis

31 March 2020

1 reference

Microtubules as a target for anticancer drugs

31 March 2020

1 reference

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

31 March 2020

1 reference

Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics

31 March 2020

1 reference

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography

31 March 2020

1 reference

Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint

31 March 2020

1 reference

How do anti-mitotic drugs kill cancer cells?

31 March 2020

1 reference

Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs.

31 March 2020

1 reference

Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.

31 March 2020

1 reference

Different phosphorylation states of the anaphase promoting complex in response to antimitotic drugs: a quantitative proteomic analysis.

31 March 2020

1 reference

Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied

31 March 2020

1 reference

The ability to survive mitosis in the presence of microtubule poisons differs significantly between human nontransformed (RPE-1) and cancer (U2OS, HeLa) cells

31 March 2020

1 reference

Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint

31 March 2020

1 reference

Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging

31 March 2020

1 reference

Tubulin proteomics: towards breaking the code.

31 March 2020

1 reference

Tubulin modifications and their cellular functions.

31 March 2020

1 reference

Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity.

31 March 2020

1 reference

Post-translational modifications regulate microtubule function

31 March 2020

1 reference

The importance of p53 location: nuclear or cytoplasmic zip code?

31 March 2020

1 reference

Microtubule-targeted anticancer agents and apoptosis

31 March 2020

1 reference

Microtubules, microtubule-interfering agents and apoptosis.

31 March 2020

1 reference

Microtubules in apoptosis induction: are they necessary?

31 March 2020

1 reference

Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim.

31 March 2020

1 reference

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

31 March 2020

1 reference

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

31 March 2020

1 reference

Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells

31 March 2020

1 reference

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

31 March 2020

1 reference

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins

31 March 2020

1 reference

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

31 March 2020

1 reference

Microtubules: a dynamic target in cancer therapy.

31 March 2020

1 reference

Do beta-tubulin mutations have a role in resistance to chemotherapy?

31 March 2020

1 reference

The role of polymorphisms at beta tubulin isotype 1 codons 167 and 200 in benzimidazole resistance in cyathostomins.

31 March 2020

1 reference

Class III β‐tubulin in human development and cancer

31 March 2020

1 reference

Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin

31 March 2020

1 reference

Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia

31 March 2020

1 reference

Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel

31 March 2020

1 reference

BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability

31 March 2020

1 reference

Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol

31 March 2020

1 reference

Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.

31 March 2020

1 reference

Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer

31 March 2020

1 reference

Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region

31 March 2020

1 reference

Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin

31 March 2020

1 reference

Cloning and characterization of the 5'-flanking region of the rat neuron-specific Class III beta-tubulin gene

31 March 2020

1 reference

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

31 March 2020

1 reference

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel

31 March 2020

1 reference

beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion.

31 March 2020

1 reference

MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents

31 March 2020

1 reference

Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome

31 March 2020

1 reference

Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels

31 March 2020

1 reference

Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells

31 March 2020

1 reference

Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study

31 March 2020

1 reference

Beta class II tubulin predominates in normal and tumor breast tissues

31 March 2020

1 reference

Beta-tubulin isotype classes II and V expression patterns in nonsmall cell lung carcinomas

31 March 2020

1 reference

Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity

31 March 2020

1 reference

Molecular mechanisms of patupilone resistance

31 March 2020

1 reference

A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation

31 March 2020

1 reference

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

31 March 2020

1 reference

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

31 March 2020

1 reference

Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.

31 March 2020

1 reference

Epothilones: better or more of the same?

31 March 2020

1 reference

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy

31 March 2020

1 reference

Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies

31 March 2020

1 reference

The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies.

31 March 2020

1 reference

Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer

31 March 2020

1 reference

Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?

31 March 2020

1 reference

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

31 March 2020

1 reference

Wild-type p53 negatively regulates the expression of a microtubule-associated protein

31 March 2020

1 reference

Structural basis for the regulation of tubulin by vinblastine

31 March 2020

1 reference

Stathmin 1: a novel therapeutic target for anticancer activity

31 March 2020

1 reference

Stathmin activity influences sarcoma cell shape, motility, and metastatic potential.

31 March 2020

1 reference

Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells

31 March 2020

1 reference

Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.

31 March 2020

1 reference

Stathmin/Op18 is a novel mediator of vinblastine activity

31 March 2020

1 reference

Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations.

31 March 2020

1 reference

Conserved microtubule-actin interactions in cell movement and morphogenesis

31 March 2020

1 reference

The cytoskeleton and cancer

31 March 2020

1 reference

Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study.

31 March 2020

1 reference

Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia

31 March 2020

1 reference

Lim kinases, regulators of actin dynamics

31 March 2020

1 reference

LIM kinase 2 is widely expressed in all tissues

31 March 2020

1 reference

Different activity regulation and subcellular localization of LIMK1 and LIMK2 during cell cycle transition

31 March 2020

1 reference

LIM-kinase 2, a regulator of actin dynamics, is involved in mitotic spindle integrity and sensitivity to microtubule-destabilizing drugs

31 March 2020

1 reference

The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel

31 March 2020

1 reference

Environment-mediated drug resistance: a major contributor to minimal residual disease

31 March 2020

1 reference

Acute and chronic in vivo therapeutic resistance

31 March 2020

1 reference

Factors determining cellular mechanisms of resistance to antimitotic drugs

31 March 2020

1 reference

Taxol stabilizes microtubules in mouse fibroblast cells

31 March 2020

1 reference

Discovery of ixabepilone.

31 March 2020

1 reference

Dynamics and mechanics of the microtubule plus end

31 March 2020

1 reference

The role of stathmin in the regulation of the cell cycle

31 March 2020

1 reference

Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.

31 March 2020

1 reference

Expression of beta-tubulin isotypes in human primary ovarian carcinoma

31 March 2020

1 reference

Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer

31 March 2020

1 reference

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

31 March 2020

1 reference

Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.

31 March 2020

1 reference

Drug resistance mechanisms in cancer cells: a proteomics perspective.

31 March 2020

1 reference

12 December 2020

1 reference

12 December 2020

Taxanes, microtubules and chemoresistant breast cancer.

1 reference

12 December 2020

Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer.

1 reference

12 December 2020

An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines

1 reference

12 December 2020

Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs

1 reference

12 December 2020

A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4.

1 reference

12 December 2020

Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.

1 reference

12 December 2020

The role of beta-tubulin isotypes in resistance to antimitotic drugs

1 reference

12 December 2020

Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.

1 reference

12 December 2020

Multiple forms of tubulin: different gene products and covalent modifications

1 reference

12 December 2020

Differential expression and cellular distribution of gamma-tubulin and betaIII-tubulin in medulloblastomas and human medulloblastoma cell lines

1 reference

12 December 2020

Overexpression of class I, II or IVb beta-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel.

1 reference

12 December 2020

DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.

1 reference

12 December 2020

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

1 reference

12 December 2020

Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation.

1 reference

12 December 2020

Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC2803

1 reference

22 August 2017

1 reference

PubMed ID

20147901